Epilepsy in pregnancy and preconception planning
Women with epilepsy · Neurology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Management of women with epilepsy before and during pregnancy to balance seizure control against teratogenic and developmental risks of antiseizure medication. Requires preconception optimisation, high-dose folate and specialist joint care.
Red flags
- New seizures after 20 weeks (exclude eclampsia/CVST)
- Status epilepticus in pregnancy
- Rising seizure frequency from falling drug levels
- Unplanned pregnancy on valproate
- Postpartum medication toxicity from un-reduced dose
Assessment
Differential diagnosis
- Eclampsia (new seizures in late pregnancy)
- Gestational exacerbation of known epilepsy
- Psychogenic non-epileptic seizures
- Cerebral venous sinus thrombosis
- Posterior reversible encephalopathy syndrome
- Hyponatraemia or metabolic seizures
Investigations
- Confirm epilepsy diagnosis and seizure type before pregnancy
- Baseline and serial lamotrigine or levetiracetam levels (clearance rises in pregnancy)
- Antiseizure medication review for teratogenic potential
- Detailed fetal anomaly ultrasound at 18-20 weeks
- Vitamin D and medication adherence assessment
- In new late-pregnancy seizures: BP, urinalysis, bloods and imaging to exclude eclampsia/CVST
Management
- Discuss contraception and planned pregnancy with every woman of childbearing potential on antiseizure medication
- Avoid sodium valproate in women who may become pregnant unless no alternative and under a pregnancy prevention programme
- Switch to lower-risk agent (lamotrigine or levetiracetam) before conception, not after
- Start folic acid 5 mg daily before conception and continue through first trimester
- Aim for monotherapy at the lowest effective dose
- Monitor lamotrigine/levetiracetam levels through pregnancy and increase dose as clearance rises
- Reduce dose back toward pre-pregnancy levels in early postpartum to avoid toxicity
- Arrange joint obstetric-neurology antenatal care and enrol in a pregnancy register
- Plan delivery with seizure precautions and continued medication
- Counsel on safe infant care (changing on floor, supervised bathing) and support breastfeeding on most agents
Drugs & doses
Folic acid 5 mg PO daily preconception and first trimester
Lamotrigine (monotherapy, dose adjusted to serum levels through pregnancy)
Levetiracetam (monotherapy, dose increased as clearance rises)
Avoid sodium valproate (high teratogenic and neurodevelopmental risk)
Vitamin K 1 mg IM to neonate at birth per local policy
Disposition
Joint neurology-obstetric specialist antenatal clinic. Enrol in epilepsy pregnancy register. Urgent assessment for new seizures in pregnancy.
Complications & pitfalls
- Major congenital malformation and neurodevelopmental harm (especially valproate)
- Breakthrough seizures from pregnancy pharmacokinetics
- Postpartum toxicity if dose not reduced
- Seizure-related maternal and fetal injury
- SUDEP risk with poor control
Exam pearls
- Optimise medication before conception, never discover epilepsy risk at the booking visit
- Lamotrigine clearance can double by late pregnancy; monitor levels and pre-empt dose rises
- Reduce lamotrigine promptly postpartum to avoid toxicity
- Most antiseizure medications are compatible with breastfeeding
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.